Find Research Outputs

Search concepts
Selected Filters
2020
1 Citation (Scopus)

Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B-precursor acute lymphoblastic leukemia

Rambaldi, A., Ribera, J. M., Kantarjian, H. M., Dombret, H., Ottmann, O. G., Stein, A. S., Tuglus, C. A., Zhao, X., Kim, C. & Martinelli, G., Jan 15 2020, In : Cancer. 126, 2, p. 304-310 7 p.

Research output: Contribution to journalArticle

Open Access
Standard of Care
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Propensity Score
Salvage Therapy
Therapeutics

Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial

Jabbour, E., Gökbuget, N., Advani, A., Stelljes, M., Stock, W., Liedtke, M., Martinelli, G., O'Brien, S., Wang, T., Laird, A. D., Vandendries, E., Neuhof, A., Nguyen, K., Dakappagari, N., DeAngelo, D. J. & Kantarjian, H., Jan 2020, In : Leukemia Research. 88, 106283.

Research output: Contribution to journalArticle

Open Access
Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Survival
Inotuzumab Ozogamicin
Disease-Free Survival
Gene Frequency
Acute Myeloid Leukemia
Mutation
Survival
Leukocyte Count
Leukemia, Myeloid, Chronic Phase
Pleural Effusion
Therapeutics
Cytogenetics
bcr-abl Fusion Proteins
Germ-Line Mutation
Myelodysplastic Syndromes
lenalidomide

Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia

Rafei, H., Kantarjian, H. M. & Jabbour, E. J., Jan 1 2020, In : British Journal of Haematology. 188, 2, p. 207-223 17 p.

Research output: Contribution to journalReview article

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Protein-Tyrosine Kinases
Therapeutics
Bispecific Antibodies
Philadelphia Chromosome
2019
7 Citations (Scopus)

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Jain, P., Kantarjian, H., Boddu, P. C., Nogueras-González, G. M., Verstovsek, S., Garcia-Manero, G., Borthakur, G., Sasaki, K., Kadia, T. M., Sam, P., Ahaneku, H., O’Brien, S., Estrov, Z., Ravandi, F., Jabbour, E. & Cortes, J. E., Mar 26 2019, In : Blood Advances. 3, 6, p. 851-861 11 p.

Research output: Contribution to journalArticle

Open Access
Leukemia, Myeloid, Chronic Phase
Protein-Tyrosine Kinases
Incidence
Confidence Intervals
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6 Citations (Scopus)

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

Savona, M. R., Odenike, O., Amrein, P. C., Steensma, D. P., DeZern, A. E., Michaelis, L. C., Faderl, S., Harb, W., Kantarjian, H. M., Lowder, J., Oganesian, A., Azab, M. & Garcia-Manero, G., Apr 1 2019, In : The Lancet Haematology. 6, 4, p. e194-e203

Research output: Contribution to journalArticle

decitabine
Myelodysplastic Syndromes
Area Under Curve
Cytidine Deaminase
3 Citations (Scopus)

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

Bose, P., Swaminathan, M., Pemmaraju, N., Ferrajoli, A., Jabbour, E. J., Daver, N., DiNardo, C., Alvarado, Y., Yilmaz, M., Huynh-Lu, J., Qiao, W., Wang, X., Matamoros Jr, A., Zhou, L., Pierce, S., Schroeder, K. D., Kantarjian, H. M. & Verstovsek, S., Jun 7 2019, In : Leukemia and Lymphoma. 60, 7, p. 1767-1774 8 p.

Research output: Contribution to journalArticle

Primary Myelofibrosis
Histone Deacetylase Inhibitors
Palpation
Splenomegaly
INCB018424
Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes
Diploidy
Cytogenetics
Survival

BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment

Piya, S., Mu, H., Bhattacharya, S., Lorenzi, P. L., Eric Davis, R., McQueen, T., Ruvolo, V., Baran, N., Wang, Z., Qian, Y., Crews, C. M., Konopleva, M., Ishizawa, J., James You, M., Kantarjian, H., Andreeff, M. & Borthakur, G., May 1 2019, In : Journal of Clinical Investigation. 129, 5, p. 1878-1894 17 p.

Research output: Contribution to journalArticle

Open Access
Stem Cell Niche
Proteolysis
Down-Regulation
Acute Myeloid Leukemia
Stem Cells
4 Citations (Scopus)

Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Stein, A. S., Kantarjian, H., Gökbuget, N., Bargou, R., Litzow, M. R., Rambaldi, A., Ribera, J. M., Zhang, A., Zimmerman, Z., Zugmaier, G. & Topp, M. S., Aug 2019, In : Biology of Blood and Marrow Transplantation. 25, 8, p. 1498-1504 7 p.

Research output: Contribution to journalArticle

Open Access
Hematopoietic Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Residual Neoplasm
blinatumomab

Blinatumomab for the treatment of acute lymphoblastic leukemia: an update

Rausch, C. R., Paul, S., Nasnas, P. E., Kantarjian, H. M. & Jabbour, E. J., Feb 1 2019, In : Expert Opinion on Orphan Drugs. 7, 2, p. 41-46 6 p.

Research output: Contribution to journalArticle

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Philadelphia Chromosome
Therapeutics
Phase III Clinical Trials
Expert Testimony
2 Citations (Scopus)

Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia

Dombret, H., Topp, M. S., Schuh, A. C., Wei, A. H., Durrant, S., Bacon, C. L., Tran, Q., Zimmerman, Z. & Kantarjian, H., Jul 29 2019, In : Leukemia and Lymphoma. 60, 9, p. 2214-2222 9 p.

Research output: Contribution to journalArticle

B-Lymphoid Precursor Cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug Therapy
Hematopoietic Stem Cell Transplantation
Chromosomes, Human, 4-5

Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment

Marks, D. I., van Oostrum, I., Mueller, S., Welch, V., Vandendries, E., Loberiza, F. R., Böhme, S., Su, Y., Stelljes, M. & Kantarjian, H. M., Oct 1 2019, In : Cancer medicine. 8, 13, p. 5959-5968 10 p.

Research output: Contribution to journalArticle

Open Access
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hospitalization
Drug Therapy
Incidence
Therapeutics
5 Citations (Scopus)

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia

Angelova, E., Audette, C., Kovtun, Y., Daver, N., Wang, S. A., Pierce, S., Konoplev, S. N., Khogeer, H., Jorgensen, J. L., Konopleva, M., Zweidler-McKay, P. A., Medeiros, L. J., Kantarjian, H. M., Jabbour, E. J. & Khoury, J. D., Mar 31 2019, In : Haematologica. 104, 4, p. 749-755 7 p.

Research output: Contribution to journalArticle

Open Access
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antibodies
Pharmaceutical Preparations
11 Citations (Scopus)

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy

Pemmaraju, N., Kantarjian, H., Nastoupil, L., Dupuis, M., Zhou, L., Pierce, S., Patel, K. P., Masarova, L., Cortes, J. & Verstovsek, S., May 23 2019, In : Blood. 133, 21, p. 2348-2351 4 p.

Research output: Contribution to journalArticle

Janus Kinases
Lymphoma
Neoplasms
Therapeutics
Second Primary Neoplasms
3 Citations (Scopus)

Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: A pooled analysis of individual patient data from nine international cohorts

Angenendt, L., Röllig, C., Montesinos, P., Martínez-Cuadrón, D., Barragan, E., García, R., Botella, C., Martínez, P., Ravandi, F., Kadia, T., Kantarjian, H. M., Cortes, J., Juliusson, G., Lazarevic, V., Höglund, M., Lehmann, S., Recher, C., Pigneux, A., Bertoli, S., Dumas, P. Y. & 25 others, Dombret, H., Preudhomme, C., Micol, J. B., Terré, C., Ráčil, Z., Novák, J., Žák, P., Wei, A. H., Tiong, I. S., Wall, M., Estey, E., Shaw, C., Exeler, R., Wagenführ, L., Stölzel, F., Thiede, C., Stelljes, M., Lenz, G., Mikesch, J. H., Serve, H., Ehninger, G., Berdel, W. E., Kramer, M., Krug, U. & Schliemann, C., Oct 10 2019, In : Journal of Clinical Oncology. 37, 29, p. 2632-2642 11 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Chromosome Aberrations
Karyotype
Cytogenetics
Abnormal Karyotype
13 Citations (Scopus)

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

Zhang, H., Savage, S., Schultz, A. R., Bottomly, D., White, L., Segerdell, E., Wilmot, B., McWeeney, S. K., Eide, C. A., Nechiporuk, T., Carlos, A., Henson, R., Lin, C., Searles, R., Ho, H., Lam, Y. L., Sweat, R., Follit, C., Jain, V., Lind, E. & 10 others, Borthakur, G., Garcia-Manero, G., Ravandi, F., Kantarjian, H. M., Cortes, J., Collins, R., Buelow, D. R., Baker, S. D., Druker, B. J. & Tyner, J. W., Dec 1 2019, In : Nature communications. 10, 1, 244.

Research output: Contribution to journalArticle

Open Access
leukemias
mutations
Acute Myeloid Leukemia
Mutation
inhibitors

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)

Tanaka, T., Morita, K., Wang, F., Little, L., Gumbs, C., Matthews, J., DiNardo, C. D., Kadia, T. M., Ravandi, F., Konopleva, M. Y., Kantarjian, H. M., Champlin, R. E., Garcia-Manero, G., Futreal, P. A. & Takahashi, K., Nov 13 2019, In : Blood. 134, 1, 1 p.

Research output: Contribution to journalArticle

Hematopoiesis
Acute Myeloid Leukemia
Research
Advisory Committees
Actinium
2 Citations (Scopus)
Myelodysplastic Syndromes
Hematopoiesis
Comorbidity
Mutation
Janus Kinase 2
B-Cell Chronic Lymphocytic Leukemia
Research
Therapeutics
Advisory Committees
PCI 32765
4 Citations (Scopus)
Mutation
Neoplasms
Germ-Line Mutation
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Transplantation (surgical)
Hematopoiesis
Graft vs Host Disease
Grafts
Transplantation
3 Citations (Scopus)
Open Access
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Therapeutics
In Vitro Techniques
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Immunophenotyping

Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling

Hibma, J. E., Kantarjian, H. M., DeAngelo, D. J. & Boni, J. P., Mar 1 2019, In : British journal of clinical pharmacology. 85, 3, p. 590-600 11 p.

Research output: Contribution to journalArticle

Hematologic Neoplasms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Non-Hodgkin's Lymphoma
Electrocardiography
B-Lymphocytes
33 Citations (Scopus)
Open Access
Azacitidine
Acute Myeloid Leukemia
Biomarkers
Safety
Bone Marrow
1 Citation (Scopus)
Open Access
B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Mutation
Research Ethics Committees
Biological Factors
Open Access
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Safety
Imatinib Mesylate
Leukemia, Myeloid, Chronic Phase
Generic Drugs

Emerging drug profile: CPX-351 (vyxeos) in AML

Alfayez, M., Kantarjian, H., Kadia, T., Ravandi-Kashani, F. & Daver, N., Jan 1 2019, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalReview article

Acute Myeloid Leukemia
Pharmaceutical Preparations
Cytarabine
Daunorubicin
Anthracyclines
8 Citations (Scopus)

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

Pollyea, D. A., Tallman, M. S., de Botton, S., Kantarjian, H. M., Collins, R., Stein, A. S., Frattini, M. G., Xu, Q., Tosolini, A., See, W. L., MacBeth, K. J., Agresta, S. V., Attar, E. C., DiNardo, C. D. & Stein, E. M., Nov 1 2019, In : Leukemia. 33, 11, p. 2575-2584 10 p.

Research output: Contribution to journalArticle

Open Access
Isocitrate Dehydrogenase
Acute Myeloid Leukemia
Proteins
Therapeutics
Hyperbilirubinemia
2 Citations (Scopus)

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia

Chung, W., Kelly, A. D., Kropf, P., Fung, H., Jelinek, J., Su, X. Y., Roboz, G. J., Kantarjian, H. M., Azab, M. & Issa, J. P. J., Jul 22 2019, In : Clinical epigenetics. 11, 1, 106.

Research output: Contribution to journalArticle

Open Access
Acute Myeloid Leukemia
Epigenomics
Mutation
Gene Expression
Hemoglobins
9 Citations (Scopus)

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

Garcia-Manero, G., Roboz, G., Walsh, K., Kantarjian, H., Ritchie, E., Kropf, P., O'Connell, C., Tibes, R., Lunin, S., Rosenblat, T., Yee, K., Stock, W., Griffiths, E., Mace, J., Podoltsev, N., Berdeja, J., Jabbour, E., Issa, J. P. J., Hao, Y., Keer, H. N. & 2 others, Azab, M. & Savona, M. R., Jun 2019, In : The Lancet Haematology. 6, 6, p. e317-e327

Research output: Contribution to journalArticle

Myelodysplastic Syndromes
decitabine
Therapeutics
SGI-110
Pneumonia
Residual Neoplasm
Acute Myeloid Leukemia
Transplantation
Transplants
Melphalan
1 Citation (Scopus)
Hematologic Neoplasms
Neoplasms
Germ-Line Mutation
Cytogenetic Analysis
Myelodysplastic Syndromes
1 Citation (Scopus)

How much of US health care spending provides direct care or benefit to patients?

Fredell, M. N., Kantarjian, H. M., Shih, Y. C. T., Ho, V. & Mukherjee, B., May 1 2019, In : Cancer. 125, 9, p. 1404-1409 6 p.

Research output: Contribution to journalComment/debate

Health Expenditures
Delivery of Health Care
Health Services Accessibility
Patient Care
Costs and Cost Analysis
34 Citations (Scopus)
B-Cell Chronic Lymphocytic Leukemia
Chromosome Deletion
Residual Neoplasm
Therapeutics
PCI 32765

Impact of Catheter Management on Clinical Outcome in Adult Cancer Patients with Gram-Negative Bacteremia

Fares, J., Khalil, M., Chaftari, A. M., Hachem, R., Jiang, Y., Kantarjian, H. M. & Raad, I. I., Sep 30 2019, In : Open Forum Infectious Diseases. 6, 10, ofz357.

Research output: Contribution to journalArticle

Open Access
Bacteremia
Catheters
Central Venous Catheters
Infection
Neoplasms
1 Citation (Scopus)
Second Primary Neoplasms
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Incidence
SEER Program
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inotuzumab Ozogamicin
16 Citations (Scopus)

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study

Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S. M., Jabbour, E., Wang, T., Liang White, J., Sleight, B., Vandendries, E. & Advani, A. S., Jul 15 2019, In : Cancer. 125, 14, p. 2474-2487 14 p.

Research output: Contribution to journalArticle

Open Access
Standard of Care
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Survival
Hepatic Veno-Occlusive Disease
B-Lymphoid Precursor Cells
1 Citation (Scopus)
Janus Kinase 2
Acute Myeloid Leukemia
Neoplasms
Primary Myelofibrosis
Mutation
5 Citations (Scopus)
Clonal Evolution
Acute Myeloid Leukemia
Leukemia
Recurrence
Therapeutics
21 Citations (Scopus)

Management of acute promyelocytic leukemia: Updated recommendations from an expert panel of the European LeukemiaNet

Sanz, M. A., Fenaux, P., Tallman, M. S., Estey, E. H., Löwenberg, B., Naoe, T., Lengfelder, E., Döhner, H., Burnett, A. K., Chen, S. J., Mathews, V., Iland, H., Rego, E., Kantarjian, H., Adès, L., Avvisati, G., Montesinos, P., Platzbecker, U., Ravandi, F., Russell, N. H. & 1 others, Lo-Coco, F., Apr 11 2019, In : Blood. 133, 15, p. 1630-1643 14 p.

Research output: Contribution to journalArticle

Acute Promyelocytic Leukemia
Therapeutics
Salvaging
Salvage Therapy
Disease Management
7 Citations (Scopus)

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality

Ishizawa, J., Zarabi, S. F., Davis, R. E., Halgas, O., Nii, T., Jitkova, Y., Zhao, R., St-Germain, J., Heese, L. E., Egan, G., Ruvolo, V. R., Barghout, S. H., Nishida, Y., Hurren, R., Ma, W., Gronda, M., Link, T., Wong, K., Mabanglo, M., Kojima, K. & 12 others, Borthakur, G., MacLean, N., Ma, M. C. J., Leber, A. B., Minden, M. D., Houry, W., Kantarjian, H., Stogniew, M., Raught, B., Pai, E. F., Schimmer, A. D. & Andreeff, M., May 13 2019, In : Cancer cell. 35, 5, p. 721-737.e9

Research output: Contribution to journalArticle

Proteolysis
Peptide Hydrolases
Mitochondrial Proteins
Electron Transport
Neoplasms
31 Citations (Scopus)

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

Stein, E. M., DiNardo, C. D., Fathi, A. T., Pollyea, D. A., Stone, R. M., Altman, J. K., Roboz, G. J., Patel, M. R., Collins, R., Flinn, I. W., Sekeres, M. A., Stein, A. S., Kantarjian, H. M., Levine, R. L., Vyas, P., MacBeth, K. J., Tosolini, A., VanOostendorp, J., Xu, Q., Gupta, I. & 7 others, Lila, T., Risueno, A., Yen, K. E., Wu, B., Attar, E. C., Tallman, M. S. & de Botton, S., Feb 14 2019, In : Blood. 133, 7, p. 676-687 12 p.

Research output: Contribution to journalArticle

Open Access
Isocitrate Dehydrogenase
Acute Myeloid Leukemia
Refractory materials
Mutation
Transplants